Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Waltham, MA, US. The stock last traded at $9.08, down 1.08% on the session, giving a market capitalisation of $59.7M. On trailing twelve-month figures it carries a trailing P/E of -6.09, a net margin of -24.1%. Its beta of -0.12 implies it has historically moved less than the broad market.
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
Xilio Therapeutics, Inc. is most often compared with the following Healthcare names: